Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S316000, C546S318000
Reexamination Certificate
active
10482264
ABSTRACT:
The invention relates to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein A, R1, R2, R3, n and m are described in the specification, useful in the treatment ofa disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.
REFERENCES:
patent: 4009174 (1977-02-01), Cluzan et al.
patent: 4105785 (1978-08-01), Mauvernay et al.
patent: 4146631 (1979-03-01), Ford et al.
patent: 4634783 (1987-01-01), Fujii et al.
patent: 5273986 (1993-12-01), Holland et al.
patent: 5399702 (1995-03-01), Holland et al.
patent: 5849735 (1998-12-01), Albright et al.
patent: 6110945 (2000-08-01), Head et al.
patent: 6200995 (2001-03-01), De la Brouse-Elwood et al.
patent: 6207693 (2001-03-01), Setoi et al.
patent: 6214878 (2001-04-01), Bernardon et al.
patent: 6316482 (2001-11-01), Setoi et al.
patent: 2001/0027200 (2001-10-01), De la Brouse-Elwood et al.
patent: 0 219 436 (1993-12-01), None
patent: 0 619 116 (1994-10-01), None
patent: 1048659 (2000-11-01), None
patent: 1 336 607 (2003-08-01), None
patent: 1357116 (2003-10-01), None
patent: 1600442 (2005-11-01), None
patent: 2088019 (1972-01-01), None
patent: 2 216 517 (1989-10-01), None
patent: 2 385 328 (2003-08-01), None
patent: 57 021320 (1982-02-01), None
patent: 6-27025 (1994-02-01), None
patent: 8-143565 (1996-06-01), None
patent: 8-173525 (1996-07-01), None
patent: 08 301760 (1996-11-01), None
patent: 11 171848 (1999-06-01), None
patent: WO 95/20578 (1995-08-01), None
patent: WO-96/11902 (1996-04-01), None
patent: WO-96/22282 (1996-07-01), None
patent: WO-96/22293 (1996-07-01), None
patent: WO-96/22294 (1996-07-01), None
patent: WO-96/22295 (1996-07-01), None
patent: WO-96/41795 (1996-12-01), None
patent: WO-97/24355 (1997-07-01), None
patent: WO-97/49707 (1997-12-01), None
patent: WO-97/49708 (1997-12-01), None
patent: WO 98/24771 (1998-06-01), None
patent: WO 98/45242 (1998-10-01), None
patent: WO-99/00359 (1999-01-01), None
patent: WO-99/00372 (1999-01-01), None
patent: WO-99/20611 (1999-04-01), None
patent: WO-99/26944 (1999-06-01), None
patent: WO 99/38845 (1999-08-01), None
patent: WO-99/54310 (1999-10-01), None
patent: WO 99/62901 (1999-12-01), None
patent: WO 00/02850 (2000-01-01), None
patent: WO 00/26202 (2000-05-01), None
patent: WO 00/39118 (2000-07-01), None
patent: WO-00/58293 (2000-10-01), None
patent: WO 01/16097 (2001-03-01), None
patent: WO-01/19788 (2001-03-01), None
patent: WO-01/20327 (2001-03-01), None
patent: WO-01/26652 (2001-04-01), None
patent: WO-01/44216 (2001-06-01), None
patent: WO-01/83465 (2001-11-01), None
patent: WO-01/83478 (2001-11-01), None
patent: WO-01/85706 (2001-11-01), None
patent: WO-01/85707 (2001-11-01), None
patent: WO-02/08209 (2002-01-01), None
patent: WO-02/14312 (2002-02-01), None
patent: WO 02/24682 (2002-03-01), None
patent: WO-02/46173 (2002-06-01), None
patent: WO-02/48106 (2002-06-01), None
patent: WO-03/000262 (2003-01-01), None
patent: WO-03/000267 (2003-01-01), None
patent: WO-03/015774 (2003-02-01), None
patent: WO-03/080585 (2003-02-01), None
patent: WO 03/047626 (2003-06-01), None
patent: WO-03/055482 (2003-07-01), None
patent: WO 03/082838 (2003-10-01), None
patent: WO-03/095438 (2003-11-01), None
patent: WO-03/097824 (2003-11-01), None
patent: WO-04/002481 (2004-01-01), None
patent: WO-04/031179 (2004-04-01), None
patent: WO 2004/045614 (2004-06-01), None
patent: WO 2004/046139 (2004-06-01), None
patent: WO 2004/050645 (2004-06-01), None
patent: WO 2004/052869 (2004-06-01), None
patent: WO 2004/063179 (2004-07-01), None
patent: WO 2004/063194 (2004-07-01), None
patent: WO 2004/072031 (2004-08-01), None
patent: WO 2004/072066 (2004-08-01), None
patent: WO 2004/076420 (2004-09-01), None
patent: WO 2004/081001 (2004-09-01), None
patent: WO 2004/085406 (2004-10-01), None
patent: WO 2004/110375 (2004-12-01), None
patent: WO 2005/044801 (2005-05-01), None
patent: WO 2005/049019 (2005-06-01), None
patent: WO 2005/054200 (2005-06-01), None
patent: WO 2005/054233 (2005-06-01), None
patent: WO 2005/056530 (2005-06-01), None
patent: WO 2005/063738 (2005-07-01), None
patent: WO 2005/066145 (2005-07-01), None
patent: WO 2005/080359 (2005-09-01), None
patent: WO 2005/080360 (2005-09-01), None
patent: WO 2005/090322 (2005-09-01), None
patent: WO 2005/095417 (2005-10-01), None
patent: WO 2005/095418 (2005-10-01), None
patent: WO 2005/103021 (2005-11-01), None
patent: WO 2005/121110 (2005-12-01), None
patent: WO 2005/123132 (2005-12-01), None
patent: WO 2006/016174 (2006-02-01), None
patent: WO 2006/016178 (2006-02-01), None
patent: WO 2006/016194 (2006-02-01), None
DeJohn et al, “Functionalization of substituted 2(1H)- and 4(1H)-pyridones. III. The preparation of substituted 6-vinyl-1,2-dihydro-2-oxo- and 1,4-dihydro-4-oxo-3-pyridinecarboxylic acids through the chemistry of pyridone dianions,” J. Heterocyclic Chem., vol. 20, pp. 1295-1302 (1983).
McKerrecher et al., “Discovery, Synthesis and Biological Evaluation of Novel Glucokinase Activators,” Bioorganic & Medicinal Chemistry Letters 15:2103-2106 (2005).
Grimsby, “Glucokinase Activators—Potential Treatment for Type 2 Diabetes,” Roche—SMI Diabetes London UK Oct. 28-29, 2002.
Levin et al., “Brain Glucose Sensing and Body Energy Homeostasis: Role in Obesity and Diabetes,” American Journal of Physiology 276:R1223-R1231 (1999).
Mastafanova et al., “Synthesis and Study of the Antihypertensive Activity of Substituted N-Acetylmercaptopropionyl-6-[2′-Phenylethyl]Pipecolinic Acids,” Khim Farm ZH 22(2) 294-302 (1998) (translation included).
Mastafanova et al., “Synthesis, Anti-Inflammatory and Analgesic Activity of 1,6-Disubstituted Pipecolic and 6-Substituted Picolinic Acids,” Khim Farm ZH, 22(4) 428-431 (1998) (translation included).
Alvarez, E. et al., “Evidence that Glucokinase Regulatory Protein is Expressed and Interacts with Glucokinase in Rat Brain,” Journal of Neurochemistry, vol. 80., pp. 45-53 (2002).
Alvarez, E. et al., “Expression of the Glucagon-Like Peptide-1 Receptor Gene in Rat Brain,” Journal of Neurochemistry, vol. 66, No. 3., pp. 920-927 (1996).
Baker, R. et al. “Structure and Synthesis of Pallescensin E Utilizing a Modified Wadsworth-Emmons Reaction,” J. Chem. Soc. Perkins Trans. 1, vol. 12 (1981).
Baker, R. et al. “Synthesis of Pallescensin-E: Use of Crown Ether in the Wadsworth Procedure for Olefin Formation,” Tetrahedron Letters, vol. 22, Pergamon Press Ltd., GB (1981).
Bell, G.I. et al., “Glucokinase Mutations, Insulin Secretion, and Diabetes Mellitus,” Annu. Rev. Physiol., vol. 58, pp. 171-186 (1996).
Beller, N.R. et al., “Photochemical Synthesis of Benzo[f]quinolines”, J. Org. Chem., vol. 42, No. 22 (1997).
Brocklehurst, K.J. et al., “Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators,” Diabetes, vol. 53, pp. 535-541 (2004).
Caro, J.F. et al., “Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes,” Horm. Metab. Res., vol. 27, pp. 19-22 (1995).
Christesen, H.B.T. et al., “The Second Activating Glucokinase Mutation (A456V) Implications for Glucose Homeostasis and Diabetes Therapy,” Diabetes, vol. 51, pp. 1240-1246 (2002).
Corbett, W.L., “Glucokinase Activators: Discovery of Novel, Orally Active Glucose Lowering Agents,” Cambridge Healthtech Institute's Eleventh Annual Molecular Medicine Tri-Conference, San Francisco, CA, Mar. 24-26, 2004.
DeFronzo, R.A., “Lilly Lecture 1987. The Triumvirate: B-Cell, Muscle, Liver. A Collusion Responsible for NIDDM,” Diabetes, vol. 37, pp. 667-687 (1988).
Desai, U.J. et al., “Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression,” Diabetes, vol. 50, pp. 2287-2295 (2001).
Ferre, T. et al, “Correction of Diabetic Alterations by
Caulkett Peter William Rodney
Currie Gordon Stuart
Hargreaves Rodney Brian
Hayter Barry Raymond
James Roger
AstraZeneca AB
Freistein Andrew B.
Morgan & Lewis & Bockius, LLP
Shameem Golam M. M.
LandOfFree
Vinyl phenyl derivatives as GLK activators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vinyl phenyl derivatives as GLK activators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vinyl phenyl derivatives as GLK activators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724453